Equities

Alliance Pharma PLC

Alliance Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)44.50
  • Today's Change0.20 / 0.45%
  • Shares traded2.01m
  • 1 Year change+16.34%
  • Beta0.8144
Data delayed at least 20 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.

  • Revenue in GBP (TTM)183.15m
  • Net income in GBP-33.58m
  • Incorporated2001
  • Employees290.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Adimmune Corp40.28m-14.78m231.83m564.00--1.86--5.76-1.44-1.443.9311.920.18481.254.04---8.270.6867-10.190.773927.8230.11-44.753.041.99-24.750.328432.80-20.7216.77-319.91--38.05--
Seikagaku Corp195.08m10.25m234.89m988.0022.010.589411.921.2036.9336.93703.071,379.480.46791.934.8838,827,940.002.460.42612.660.467847.9854.185.250.98144.53--0.0051465.788.244.99-2.24-0.522430.280.00
Shanghai Serum Bio-Technology Co Ltd21.52m5.55m235.27m321.0042.351.94--10.930.47060.47061.8210.300.17351.143.91614,647.904.4810.434.5610.8476.6080.5425.8132.5742.72--0.00464.939.145.67-39.54-1.6213.07--
PharmaSGP Holding SE91.47m15.18m238.02m93.0015.678.7510.352.601.521.529.152.720.82231.048.571,233,225.0013.6413.7018.3419.9890.9190.2016.5917.561.5414.980.6823--17.8010.7837.172.1625.88--
Alliance Pharma plc183.15m-33.58m239.47m290.00--1.07--1.31-0.0622-0.06220.33780.41240.40162.724.67627,215.80-7.36-0.5982-8.08-0.656659.4262.45-18.34-1.802.064.450.3218--7.928.86-56.24---25.01--
Golden Throat Holdings Group Co Ltd109.87m28.63m239.49m860.008.361.717.282.180.38140.38141.461.870.49943.234.071,245,056.0013.0111.0019.2615.6372.2972.7926.0624.671.9337.740.281483.15-3.096.73-11.0419.61-32.1338.94
Shanghai Shen Lian Biomedical Corp33.86m-2.15m245.92m380.00--1.54--7.26-0.048-0.0480.75583.560.19441.160.9692816,747.00-1.485.39-1.585.8460.6677.45-7.6225.485.14--0.001238.49-8.251.85-48.41-18.4910.47--
Themis Medicare Ltd39.38m4.96m246.80m1.54k49.766.3941.166.275.755.7545.6344.760.73062.392.222,727,670.009.2111.1212.5716.4664.6460.3212.6114.961.56--0.16517.597.7415.75-23.51--26.73--
Data as of Nov 21 2024. Currency figures normalised to Alliance Pharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

44.42%Per cent of shares held by top holders
HolderShares% Held
Slater Investments Ltd.as of 22 Jul 202470.68m13.07%
Lombard Odier Asset Management (Europe) Ltd.as of 09 Oct 202427.26m5.04%
Rathbones Investment Management Ltd.as of 06 Oct 202325.97m4.80%
Polar Capital LLPas of 03 Sep 202421.53m3.98%
Fidelity Management & Research Co. LLCas of 11 Jun 202419.64m3.63%
Artemis Investment Management LLPas of 11 Jun 202417.35m3.21%
Van Lanschot Kempen Investment Management NVas of 18 Jun 202415.02m2.78%
RBC Global Asset Management (UK) Ltd.as of 25 Aug 202314.55m2.69%
Bill & Melinda Gates Foundation Trust (Investment Management)as of 03 Sep 202414.35m2.66%
Rowan Dartington & Co. Ltd. (Broker)as of 03 Sep 202413.76m2.55%
More ▼
Data from 30 Apr 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.